Published in Proc Natl Acad Sci U S A on March 15, 1991
In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1992) 1.67
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med (1999) 1.61
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. Mol Cell (2015) 1.36
Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res (1992) 1.33
Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Mol Cell Biol (1995) 1.24
Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1992) 1.14
The importance of the linker connecting the repeats of the c-Myb oncoprotein may be due to a positioning function. Nucleic Acids Res (1996) 1.10
Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci U S A (1992) 1.09
Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis. Blood (2008) 1.04
Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis (2012) 1.00
Myb proteins: angels and demons in normal and transformed cells. Front Biosci (Landmark Ed) (2011) 0.96
Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS One (2010) 0.95
Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation. Cell Cycle (2013) 0.93
Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching fluorescent reporter molecules. Nucleic Acids Res (2005) 0.92
Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci U S A (1996) 0.90
c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells. Leukemia (2011) 0.89
Antisense pro-drugs: 5'-ester oligodeoxynucleotides. Nucleic Acids Res (1994) 0.80
Myb expression is critical for myeloid leukemia development induced by Setbp1 activation. Oncotarget (2016) 0.78
c-Myb regulates cell cycle-dependent expression of Erbin: an implication for a novel function of Erbin. PLoS One (2012) 0.77
Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis. Am J Hematol (2012) 0.76
Stress-induced phosphorylation of Thr486 in c-Myb by p38 mitogen-activated protein kinases attenuates conjugation of SUMO-2/3. J Biol Chem (2013) 0.76
Expression of p89(c-Mybex9b), an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells. Blood Cancer J (2012) 0.76
c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia. Biomark Res (2016) 0.75
SETBP1 dysregulation in congenital disorders and myeloid neoplasms. Oncotarget (2017) 0.75
Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature (1988) 5.72
Differential expression of the amv gene in human hematopoietic cells. Proc Natl Acad Sci U S A (1982) 4.37
Expression of myb, myc and fos proto-oncogenes during the differentiation of a murine myeloid leukaemia. Nature (1984) 4.29
The v-myb oncogene product binds to and activates the promyelocyte-specific mim-1 gene. Cell (1989) 3.91
Modulation of eukaryotic gene expression by complementary RNA or DNA sequences. Biotechniques (1990) 3.61
Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell (1986) 3.59
Subcellular localization of proteins encoded by oncogenes of avian myeloblastosis virus and avian leukemia virus E26 and by chicken c-myb gene. Cell (1984) 2.98
A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science (1988) 2.88
Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol Cell Biol (1988) 2.70
Human c-myb protooncogene: nucleotide sequence of cDNA and organization of the genomic locus. Proc Natl Acad Sci U S A (1986) 2.47
Studies of the human c-myb gene and its product in human acute leukemias. Science (1986) 2.10
Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division. Proc Natl Acad Sci U S A (1986) 1.99
An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci U S A (1989) 1.98
Avian myeloblastosis virus and E26 virus oncogene products are nuclear proteins. Proc Natl Acad Sci U S A (1984) 1.97
G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. Science (1989) 1.96
Down-regulation of c-myb gene expression is a prerequisite for erythropoietin-induced erythroid differentiation. Proc Natl Acad Sci U S A (1988) 1.65
Developmental regulation of c-myb in normal myeloid progenitor cells. Proc Natl Acad Sci U S A (1985) 1.49
Lithotripsy. Health and Public Policy Committee, American College of Physicians. Ann Intern Med (1985) 1.42
Proto-oncogenes and human cancers. N Engl J Med (1987) 1.17
Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. J Clin Invest (1990) 1.13
Acute myelogenous leukemia: recent advances in therapy. Blood (1987) 1.11
Lineage-specific requirement of c-abl function in normal hematopoiesis. Science (1989) 1.09
Altered expression of G1-specific genes in human malignant myeloid cells. Proc Natl Acad Sci U S A (1986) 1.07
The myeloid progenitor cell--its value in predicting hematopoietic recovery after autologous bone marrow transplantation. Blood (1980) 1.04
Relationship between the c-myb locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science (1987) 0.98
Role of natural killer cells, in comparison with T lymphocytes and monocytes, in the regulation of normal human megakaryocytopoiesis in vitro. J Immunol (1987) 0.94
Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood (1989) 0.85
Acute lymphoblastic leukemia in adults: recent progress, future directions. Semin Hematol (1987) 0.81
Evaluation of drugs for elimination of leukemic cells from the bone marrow of patients with acute leukemia. Blood (1988) 0.79
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res (1998) 3.56
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
Real time detection of DNA.RNA hybridization in living cells. Proc Natl Acad Sci U S A (1998) 3.10
Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line. J Immunol (1987) 2.54
Hematological characterization of congenital osteopetrosis in op/op mouse. Possible mechanism for abnormal macrophage differentiation. J Exp Med (1982) 2.39
KDR receptor: a key marker defining hematopoietic stem cells. Science (1999) 2.13
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med (1994) 2.09
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma (2002) 2.04
An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci U S A (1989) 1.98
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol (2001) 1.96
G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. Science (1989) 1.96
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science (1991) 1.93
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol (2008) 1.82
The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci U S A (2001) 1.78
Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood (1987) 1.77
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood (1995) 1.69
STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A (1994) 1.67
In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1992) 1.67
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia (1992) 1.60
Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res (2001) 1.51
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med (1995) 1.48
Cell cycle-dependent initiation and lineage-dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors. Proc Natl Acad Sci U S A (1992) 1.45
Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest (1995) 1.44
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia. Proc Natl Acad Sci U S A (1986) 1.41
Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med (1992) 1.41
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol (2011) 1.34
BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat (2006) 1.33
Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J Immunol (1982) 1.30
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia (2009) 1.28
Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem (1989) 1.27
Effect of Abelson murine leukemia virus on granulocytic differentiation and interleukin-3 dependence of a murine progenitor cell line. Oncogene (1987) 1.26
Activation of c-myb expression by phytohemagglutinin stimulation in normal human T lymphocytes. Mol Cell Biol (1985) 1.22
A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet (2005) 1.22
Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplant (2000) 1.19
Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A (1994) 1.19
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood (1995) 1.18
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol (2008) 1.18
A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood (1996) 1.17
T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res (1996) 1.17
Differential expression and functional role of GATA-2, NF-E2, and GATA-1 in normal adult hematopoiesis. J Clin Invest (1995) 1.13
Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. J Clin Invest (1990) 1.13
Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood (1998) 1.11
Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res (1996) 1.11
Recent developments in renal cell cancer immunotherapy. Expert Opin Biol Ther (2007) 1.09
Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc Natl Acad Sci U S A (1992) 1.09
Lineage-specific requirement of c-abl function in normal hematopoiesis. Science (1989) 1.09
Transcriptional regulation of two myeloid-specific genes, myeloperoxidase and lactoferrin, during differentiation of the murine cell line 32D C13. Blood (1991) 1.09
Oncogenes, protooncogenes, and tumor suppressor genes in acute myelogenous leukemia. J Pediatr Hematol Oncol (1995) 1.08
Key functional role and lineage-specific expression of selected HOXB genes in purified hematopoietic progenitor differentiation. Blood (1994) 1.08
Haematologic effects of granulocyte-macrophage colony stimulating factor in a patient with thiamazole-induced agranulocytosis. J Intern Med (1992) 1.07
The localization of the human myeloperoxidase gene is in close proximity to the translocation breakpoint in acute promyelocytic leukemia. Leukemia (1987) 1.07
Altered expression of G1-specific genes in human malignant myeloid cells. Proc Natl Acad Sci U S A (1986) 1.07
2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing. Nucleic Acids Res (2006) 1.04
Chemokine regulation of human megakaryocytopoiesis. Blood (1995) 1.04
Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci U S A (1994) 1.04
Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol (1989) 1.04
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia (2009) 1.04
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer (1999) 1.03
Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther (1997) 1.03
Bell's palsy and herpes simplex virus. Arch Otolaryngol (1981) 1.02
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia (2000) 1.02
PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood (2000) 1.02
Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines. J Immunol (1993) 1.02
In vitro human immunodeficiency virus-1 infection of purified hematopoietic progenitors in single-cell culture. Blood (1995) 1.02
Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells. Stem Cells (2001) 1.02
Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. J Biol Chem (1995) 1.02
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood (1993) 1.01
Expression of c-myb protooncogene and other cell cycle-related genes in normal and neoplastic human colonic mucosa. Cancer Res (1987) 1.00
Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant (2004) 1.00
Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J Exp Med (1992) 1.00
Myb and ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. Blood (1998) 1.00